文献速递心脑血管急症

急性冠脉综合征患者与非急性冠脉综合征患者降阶为替格瑞洛单药治疗对比12个月双联抗血小板治疗:随机试验的系统综述与个体患者水平荟萃分析

De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials.
PubMed 文献 · Lancet · 2024-08-31
一句话结论与12个月DAPT相比,短期DAPT后降阶为替格瑞洛单药不增加缺血风险且降低大出血,ACS患者获益更明显。

该系统综述与个体患者水平荟萃分析纳入6项随机试验,比较药物洗脱支架植入后短期DAPT(2周至3个月)后降阶为替格瑞洛单药(90 mg每日两次)与继续12个月DAPT。在意向治疗人群24 407例中,替格瑞洛单药组BARC 3或5级出血(0.9% vs 2.1%;HR 0.43 [95% CI 0.34-0.54];p<0.0001)和全因死亡(0.9% vs 1.2%;HR 0.76 [0.59-0.98];p=0.034)均低于DAPT组。符合方案人群23 256例中MACCE发生率为2.8% vs 3.2%(HR 0.91 [95% CI 0.78-1.07];非劣效性p=0.0039)。作者认为降阶为替格瑞洛单药不增加缺血风险并降低大出血,尤其在ACS患者中。

要点

  • 在24 407例意向治疗人群中,替格瑞洛单药组BARC 3或5级出血 Kaplan-Meier 估计0.9% vs DAPT组2.1%(HR 0.43 [95% CI 0.34-0.54];优越性p<0.0001)。
  • 在23 256例符合方案人群中,MACCE(全因死亡、心肌梗死或卒中复合终点)替格瑞洛单药组2.8% vs DAPT组3.2%(HR 0.91 [95% CI 0.78-1.07];非劣效性p=0.0039)。
  • 全因死亡替格瑞洛单药组0.9% vs DAPT组1.2%(HR 0.76 [95% CI 0.59-0.98];优越性p=0.034)。
  • MACCE(p interaction=0.041)和全因死亡(p interaction=0.050)的治疗效应按性别存在异质性,提示女性可能从替格瑞洛单药治疗中获益。
  • 出血的治疗效应按临床 presentation 存在异质性(p interaction=0.022),提示ACS患者从替格瑞洛单药治疗中获益。

适用人群与场景

  • 接受经皮冠状动脉介入治疗并植入冠状动脉药物洗脱支架的患者。
  • 降阶发生在干预后中位78天(IQR 31-92),治疗中位持续时间334天(329-365)。
  • 排除有长期口服抗凝药指征的患者。

诊断标准与关键阈值

  • MACCE定义为全因死亡、心肌梗死或卒中的复合终点。
  • 出血终点为Bleeding Academic Research Consortium(BARC)3或5级出血。
  • 主要终点按以下顺序检验:在符合方案人群中检验MACCE的非劣效性(单侧α=0.025,预设非劣效性界值1.15 [风险比尺度]);在意向治疗人群中检验BARC 3或5级出血和全因死亡的优越性(双侧α=0.05)。

处置流程与药物剂量

  • 短期DAPT(2周至3个月)后降阶为替格瑞洛单药治疗,剂量90 mg每日两次。

研究设计与关键结果

  • 研究类型:系统综述与个体患者水平荟萃分析,纳入6项随机试验,共筛查8361条唯一引文,其中610条记录在题目和摘要筛选中被认为可能合格。
  • 符合方案人群23 256例中,MACCE替格瑞洛单药组297例(Kaplan-Meier估计2.8%)vs DAPT组332例(3.2%),HR 0.91(95% CI 0.78-1.07),非劣效性p=0.0039,τ²<0.0001。
  • 意向治疗人群24 407例中,BARC 3或5级出血替格瑞洛单药组Kaplan-Meier估计0.9% vs DAPT组2.1%,HR 0.43(95% CI 0.34-0.54),优越性p<0.0001,τ²=0.079。
  • 全因死亡替格瑞洛单药组Kaplan-Meier估计0.9% vs DAPT组1.2%,HR 0.76(95% CI 0.59-0.98),优越性p=0.034,τ²<0.0001。
  • 试验序贯分析显示,在总体和ACS人群中,MACCE非劣效性和出血优越性有强证据(z曲线跨越监测边界或所需信息量,未跨越无效边界或接近无效线)。
  • 按性别分层,MACCE(p interaction=0.041)和全因死亡(p interaction=0.050)的治疗效应存在异质性,提示女性可能从替格瑞洛单药治疗中获益。
  • 按临床 presentation 分层,出血的治疗效应存在异质性(p interaction=0.022),提示ACS患者从替格瑞洛单药治疗中获益。

证据类型、等级与局限

  • 证据类型:系统综述与个体患者水平荟萃分析。
  • 偏倚风险使用修订版Cochrane偏倚风险工具评估。

对床旁实践的改变

  • 作者认为,与12个月DAPT相比,降阶为替格瑞洛单药不增加缺血风险并降低大出血风险,尤其在ACS患者中。
  • 作者认为,替格瑞洛单药治疗可能与死亡率获益相关,尤其在女性中,但需进一步研究。

指南或共识出处

  • 研究注册于PROSPERO(CRD42024506083)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Dual antiplatelet therapy (DAPT) for 12 months is the standard of care after coronary stenting in patients with acute coronary syndrome (ACS). The aim of this individual patient-level meta-analysis was to summarise the evidence comparing DAPT de-escalation to ticagrelor monotherapy versus continuing DAPT for 12 months after coronary drug-eluting stent implantation.

METHODS: A systematic review and individual patient data (IPD)-level meta-analysis of randomised trials with centrally adjudicated endpoints was performed to evaluate the comparative efficacy and safety of ticagrelor monotherapy (90 mg twice a day) after short-term DAPT (from 2 weeks to 3 months) versus 12-month DAPT in patients undergoing percutaneous coronary intervention with a coronary drug-eluting stent. Randomised trials comparing P2Y12 inhibitor monotherapy with DAPT after coronary revascularisation were searched in Ovid MEDLINE, Embase, and two websites (www.tctmd.com and www.escardio.org) from database inception up to May 20, 2024. Trials that included patients with an indication for long-term oral anticoagulants were excluded. The risk of bias was assessed using the revised Cochrane risk-of-bias tool. The principal investigators of the eligible trials provided IPD by means of an anonymised electronic dataset. The three ranked coprimary endpoints were major adverse cardiovascular or cerebrovascular events (MACCE; a composite of all-cause death, myocardial infarction, or stroke) tested for non-inferiority in the per-protocol population; and Bleeding Academic Research Consortium (BARC) 3 or 5 bleeding and all-cause death tested for superiority in the intention-to-treat population. All outcomes are reported as Kaplan-Meier estimates. The non-inferiority was tested using a one-sided α of 0·025 with the prespecified non-inferiority margin of 1·15 (hazard ratio [HR] scale), followed by the ranked superiority testing at a two-sided α of 0·05. This study is registered with PROSPERO (CRD42024506083).

FINDINGS: A total of 8361 unique citations were screened, of which 610 records were considered potentially eligible during the screening of titles and abstracts. Of these, six trials that randomly assigned patients to ticagrelor monotherapy or DAPT were identified. De-escalation took place a median of 78 days (IQR 31-92) after intervention, with a median duration of treatment of 334 days (329-365). Among 23 256 patients in the per-protocol population, MACCE occurred in 297 (Kaplan-Meier estimate 2·8%) with ticagrelor monotherapy and 332 (Kaplan-Meier estimate 3·2%) with DAPT (HR 0·91 [95% CI 0·78-1·07]; p=0·0039 for non-inferiority; τ2<0·0001). Among 24 407 patients in the intention-to-treat population, the risks of BARC 3 or 5 bleeding (Kaplan-Meier estimate 0·9% vs 2·1%; HR 0·43 [95% CI 0·34-0·54]; p<0·0001 for superiority; τ2=0·079) and all-cause death (Kaplan-Meier estimate 0·9% vs 1·2%; 0·76 [0·59-0·98]; p=0·034 for superiority; τ2<0·0001) were lower with ticagrelor monotherapy. Trial sequential analysis showed strong evidence of non-inferiority for MACCE and superiority for bleeding among the overall and ACS populations (the z-curve crossed the monitoring boundaries or the required information size without crossing the futility boundaries or approaching the null). The treatment effects were heterogeneous by sex for MACCE (p interaction=0·041) and all-cause death (p interaction=0·050), indicating a possible benefit in women with ticagrelor monotherapy, and by clinical presentation for bleeding (p interaction=0·022), indicating a benefit in ACS with ticagrelor monotherapy.

INTERPRETATION: Our study found robust evidence that, compared with 12 months of DAPT, de-escalation to ticagrelor monotherapy does not increase ischaemic risk and reduces the risk of major bleeding, especially in patients with ACS. Ticagrelor monotherapy might also be associated with a mortality benefit, particularly among women, which warrants further investigation.

FUNDING: Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Valgimigli M, Hong SJ, Gragnano F, et al. De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials. Lancet. 2024. PMID: 39226909. doi:10.1016/S0140-6736(24)01616-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。